RBC Maintains Outperform on Johnson & Johnson (JNJ) Feb 2026

The JNJ analyst rating remained Outperform when RBC Capital maintained its call and raised the price target to $255 from $240 on February 3, 2026. RBC cited durable pharmaceutical cash flows and expected resilience in medical devices as reasons for the maintained view. The firm released the note at 09:33 AM and the change included a target lift rather than a shift in rating. This action signals continued analyst confidence while keeping direction neutral for short-term trading.